Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT

EJNMMI Research

Table 6 Cytogenetics and laboratory follow-up in 3 patients with discrepant findings

		At baseline	At PET/CT imaging	At FU BM	After consolidation
		At baseline	At PET/CT imaging	At FU BM	1 month	4 months	10 months	16 months
Pt 6	Cytogenetics	46, XX, t(8;21)(q22;q22)[19]/46,XX[1]
	WBC (× 10⁹/L)	17.34	0.68	3.41	4.47	17.16	–^a	–^a
	Hb (g/dL)	7	9.6	10.8	11	13.2	–^a	–^a
	Platelet (× 10⁹/L)	10	21	13	70	30	–^a	–^a
	LDH (U/L)	571	169	343	246	1041	–^a	–^a
Pt 7	Cytogenetics	43-45, XY, del(3)(p11.2), del(5)(q13q33),−7,+8,del(12)(p11.2p11.2), −21[cp20]
	WBC (× 10⁹/L)	19.02	0.85	3.09	3.3	8.2	–^a	–^a
	Hb (g/dL)	4.6	9.1	7.7	9	9.4	–^a	–^a
	Platelet (× 10⁹/L)	10	32	176	170	38	–^a	–^a
	LDH (U/L)	606	347	229	178	418	–^a	–^a
Pt 9	Cytogenetics	45,X,−Y, t(8;21)(q22;q22), add(14)(q32)[20] : RUNX1-RUNX1T1
	WBC (× 10⁹/L)	30.72	0.66	5.38	11.41	4.65	4.65	6.13
	Hb (g/dL)	3	10.3	12.5	10.5	13.7	15.4	15.2
	Platelet (× 10⁹/L)	11	55	297	49	97	97	105
	LDH (U/L)	706	310	227	306	151	153	178

Pt patient
^aPatient 6 and 7 relapsed or were strongly suspected of relapse at 4 months after consolidation